Outcome/subgroup | Women | Men | OR/B of women (95% CI) | P for interaction |
---|---|---|---|---|
In-hospital mortality | Â | Â | Â | 0.188 |
 PCI | 1277 (9.8%) | 1184 (9.1%) | 1.09 (1.001–1.19) |  |
 CABG | 360 (21.0%) | 371 (21.6%) | 0.96 (0.82–1.14) |  |
IABP support | Â | Â | Â | 0.070 |
 PCI | 1435 (11.0%) | 1691 (12.9%) | 0.83 (0.77–0.90) |  |
 CABG | 660 (38.5%) | 677 (39.5%) | 0.96 (0.84–1.10) |  |
ECMO support | Â | Â | Â | 0.236 |
 PCI | 95 (0.7%) | 147 (1.1%) | 0.64 (0.49–0.83) |  |
 CABG | 105 (6.1%) | 129 (7.5%) | 0.80 (0.62–1.05) |  |
New onset ischemic stroke | Â | Â | Â | 0.758 |
 PCI | 235 (1.8%) | 197 (1.5%) | 1.20 (0.99–1.45) |  |
 CABG | 72 (4.2%) | 57 (3.3%) | 1.28 (0.90–1.82) |  |
Pneumonia | Â | Â | Â | 0.694 |
 PCI | 995 (7.6%) | 1118 (8.6%) | 0.88 (0.81–0.96) |  |
 CABG | 162 (9.4%) | 190 (11.1%) | 0.84 (0.67–1.05) |  |
GI bleeding | Â | Â | Â | 0.825 |
 PCI | 799 (6.1%) | 796 (6.1%) | 1.00 (0.91–1.11) |  |
 CABG | 74 (4.3%) | 71 (4.1%) | 1.04 (0.75–1.46) |  |
New onset dialysis | Â | Â | Â | 0.223 |
 PCI | 784 (6.0%) | 740 (5.7%) | 1.07 (0.96–1.18) |  |
 CABG | 301 (17.5%) | 317 (18.5%) | 0.94 (0.79–1.12) |  |
Prolonged ventilationa | Â | Â | Â | 0.880 |
 PCI | 1265 (9.7%) | 1242 (9.5%) | 1.02 (0.94–1.11) |  |
 CABG | 587 (34.2%) | 574 (33.4%) | 1.03 (0.90–1.19) |  |
Hospital stays (days) |  |  |  |  < 0.001 |
 PCI | 10.6 ± 12.1 | 10.0 ± 11.8 | 0.69 (0.40, 0.98) |  |
 CABG | 28.3 ± 20.1 | 25.8 ± 18.8 | 2.5 (1.2, 3.8) |  |
ICU duration (days) | Â | Â | Â | 0.007 |
 PCI | 4.9 ± 6.5 | 4.8 ± 6.4 | 0.17 (0.02, 0.33) |  |
 CABG | 13.0 ± 11.1 | 12.1 ± 10.8 | 0.87 (0.14, 1.60) |  |
Medical expenditure (USD × 103) |  |  |  | 0.001 |
 PCI | 7.8 ± 5.6 | 7.8 ± 5.7 | 0.04 (− 0.10, 0.17) |  |
 CABG | 20.1 ± 9.9 | 19.3 ± 9.7 | 0.78 (0.12, 1.44) |  |